Tarlatamab induces response in relapsed small cell lung cancer
Click Here to Manage Email Alerts
Tarlatamab exhibited activity among patients with relapsed or refractory small cell lung cancer, according to the agent’s manufacturer.
Tarlatamab (AMG 757, Amgen) is a bispecific T-cell engager molecule that targets delta-like ligand 3 (DLL3).
The phase 2 DeLLphi-301 study assessed tarlatamab for patients with small cell lung cancer who failed at least two prior lines of treatment.
Objective response rate served as the primary endpoint.
Tarlatamab induced durable responses at a rate that substantially exceeded what had been reported in a prior phase 1 study, according to an Amgen press release.
The agent also exhibited a more favorable safety and tolerability profile than had been observed in the phase 1 study.
Complete results from DeLLphi-301 will be presented at a medical meeting. Amgen officials intend to discuss the data with regulatory agencies, according to the release.
Enrollment is underway for the phase 3 DeLLphi-304 study, which will assess tarlatamab with standard chemotherapy as second-line treatment for patients with small cell lung cancer.
Amgen also intends to launch two other phase 3 studies of tarlatamab as earlier-line treatment of small cell lung cancer.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts